title: Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center.
abstract: BACKGROUND
  Hepatorenal syndrome (HRS) is one of the serious complications in patients with advanced cirrhosis and ascites. In tertiary centers, most patients were classified as having type 1 HRS for their rapid progressive diseases. However, no significant predictors have been assessed previously for patients with type 1 HRS. In addition to the initial model of end-stage liver disease (MELD) scores and biochemistry parameters, we want to further investigate the prognostic importance of changes in MELD scores and biochemistry parameters over time for patients with type 1 HRS.
  
  
  METHODS
  Data from type 1 HRS patients were incorporated, including their demographic, clinical progression, all recording biochemical parameters, therapeutic methods, and outcomes.
  
  
  RESULTS
  A total of 103 patients were included in our study. According to the definition of the International Ascites Club, 67 patients (or 65%) had type 1 HRS whereas 36 (or 35%) had type 2 HRS. According to the multivariate COX proportional hazards regression model, either initial biochemistry parameters or MELD scores were not significantly associated with prognosis. By time-dependent proportional hazards model, each point elevated in creatinine (CRE) and total bilirubin (TBI) levels during the admission increased mortality risk by 29 and 4%, respectively. Increasing albumin level during the admission showed its protective value. Changes in MELD score simple during the admission, which were calculated by CRE and TBI [3.8 × log (bilirubin (mg/dl)] + 9.6 × log [Creatinine (mg/dl) + 6.43], were significant predictor for patients with type 1 HRS.
  
  
  CONCLUSIONS
  In patients with type 1 HRS, changes in TBI, CRE, and albumin level during the admission were associated with prognosis. Changes in MELD score simple is superior to initial and changes in MELD scores to predict prognosis in patients with type 1 HRS.
authors.forename: Ya-Wen
authors.initials: YW
authors.lastname: Yang
authors.forename: Che-Hsiung
authors.initials: CH
authors.lastname: Wu
authors.forename: Rey-Heng
authors.initials: RH
authors.lastname: Hu
authors.forename: Ming-Chin
authors.initials: MC
authors.lastname: Ho
authors.forename: Meng-Kun
authors.initials: MK
authors.lastname: Tsai
authors.forename: Yao-Ming
authors.initials: YM
authors.lastname: Wu
authors.forename: Po-Huang
authors.initials: PH
authors.lastname: Lee
references.citation: Dig Dis Sci. 2006 Jul;51(7):1203-5
references.pmid: 16944010
references.citation: Lancet. 2003 Nov 29;362(9398):1819-27
references.pmid: 14654322
references.citation: J Hepatol. 2003;38 Suppl 1:S69-89
references.pmid: 12591187
references.citation: Liver Int. 2006 Sep;26(7):834-9
references.pmid: 16911466
references.citation: Ther Apher Dial. 2006 Apr;10(2):108-17
references.pmid: 16684211
references.citation: J Hepatol. 2004 Jun;40(6):897-903
references.pmid: 15158328
references.citation: Nephrol Dial Transplant. 2006 Feb;21(2):478-82
references.pmid: 16249201
references.citation: Liver Transpl. 2003 Jan;9(1):12-8
references.pmid: 12514767
references.citation: Hepatology. 2005 Jun;41(6):1282-9
references.pmid: 15834937
references.citation: Am J Transplant. 2004 Nov;4(11):1798-804
references.pmid: 15476479
references.citation: J Hepatol. 2005 Jun;42(6):826-32
references.pmid: 15885353
references.citation: Gastroenterol Clin Biol. 2000 Mar;24(3):378-9
references.pmid: 10866518